Company: EDSA
Filing Date: 2025-03-11
Form Type: 424B3
Source: 0001171843-25-001403
Chunk: 16

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-11
Form: 424B3
Chunk 16
---
 to issue an unlimited
number of common shares and preferred shares, no par value. As of February 28, 2025, there were 6,992,625 common shares outstanding, 150
Series A-1 Shares (as defined below) outstanding and 834 Preferred Shares outstanding.

#### Common Shares
The holders of our common shares are
entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders. Our shareholders do not have
cumulative voting rights in the election of directors. The holders of common shares are entitled to receive ratably only those dividends
as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders
of our common shares are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences
of any outstanding preferred shares. Holders of common shares have no preemptive or other subscription or conversion rights. There are
no redemption or sinking fund provisions applicable to our common shares. Common shares outstanding, and to be issued, are, and will be,
fully paid and non-assessable. Additional shares of authorized common shares may be issued, as authorized by our board of directors from
time to time, without shareholder approval, except as may be required by The Nasdaq Capital Market.

#### Preferred Shares
Pursuant to our Amended and Restated
Articles (as amended, our “Articles”) and the provisions of the British Columbia Business Corporations Act, our board
of directors has the authority, without further action by the shareholders (unless such shareholder action is required by applicable law
or the rules of The Nasdaq Capital Market), to designate and issue an unlimited number of preferred shares in one of more series, to establish
from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences and rights of
the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, and to increase or decrease the
number of shares of any such series, but not below the number of shares of such series then outstanding. Preferred shares, if issued,
will be fully paid and non-assessable.

The board of directors’ authority
to determine the terms of any such preferred shares include, without limitation: (i) the designation of each series and the number of
preferred shares that will constitute each such series; (ii) the dividend rate or amount,